Highlights
- Prescient Therapeutics (ASX:PTX) has reached 20 evaluable patients in its Phase 2a PTX-100 study for relapsed or refractory cutaneous T-cell lymphoma.
- The milestone triggers the study’s first Dose Optimisation Committee review, scheduled for later in 2026.
- The study ultimately targets 40 evaluable patients across Australia, the United States and Europe.
- Trial progress, funding runway and recruitment toward the next review point remain the main areas to watch.
Prescient Therapeutics (ASX:PTX) has reached an important operational milestone in the Phase 2a study of PTX-100 for relapsed or refractory cutaneous T-cell lymphoma, with 20 evaluable patients now enrolled across the two dosing arms.
The milestone does not provide efficacy data, but it does trigger the first planned Dose Optimisation Committee review and gives the company a clearer clinical pathway into the next stage of the study.
What was announced, and when
In early September 2026, Prescient Therapeutics (ASX:PTX) said its Phase 2a PTX-100 study had reached 20 evaluable patients.
The participants are split evenly across two dosing arms.
Under the study design, a patient is considered evaluable only after completing four treatment cycles.
Reaching 20 evaluable patients represents the pre-specified threshold for the first Dose Optimisation Committee review, which is scheduled for December 2026.
The full study is targeting 40 evaluable patients across clinical sites in Australia, the United States and Europe.
That means the current milestone represents the halfway point in terms of evaluable patient numbers, but not necessarily in terms of overall clinical development.
The company and the candidate
Prescient Therapeutics (ASX:PTX) is a clinical-stage oncology company with two main development areas: small-molecule therapeutics and cell-therapy platforms.
PTX-100 sits within the small-molecule portfolio.
The drug is a geranylgeranyl transferase-1 inhibitor designed to interfere with signalling pathways Downstream of Ras.
Prescient describes the mechanism as first-in-class.
PTX-100 also has US Orphan Drug designation covering T-cell lymphomas and fast-track designation for relapsed or refractory mycosis fungoides, one of the more common forms of cutaneous T-cell lymphoma.
These regulatory designations can provide development and review advantages, but they do not establish clinical effectiveness or guarantee approval.
The company’s OmniCAR and CellPryme platforms are separate cell-therapy programs and remain pre-clinical.
Why the milestone matters
The significance of the 20-patient threshold is primarily operational.
It shows that recruitment has progressed far enough for the trial’s first planned dose and safety review to take place.
The Dose Optimisation Committee is intended to assess accumulated study information and guide how the trial proceeds across its dosing arms.
That can include recommendations around continuation, modification or dose selection.
However, the milestone should not be interpreted as evidence that PTX-100 is effective.
The company has not disclosed a formal interim efficacy readout linked to the 20-patient threshold.
The more meaningful clinical evidence will come from later study data assessing patient outcomes, durability of response, safety and dose performance.
Funding and the runway
Clinical development remains Capital intensive, making funding an important part of the PTX-100 story.
Prescient Therapeutics (ASX:PTX) opened a share purchase plan in late August 2026 seeking to raise up to A$7 million.
The closing date was subsequently extended into mid-September following delays in delivery of offer documentation.
At 30 June 2026, the company reported cash of approximately A$9.03 million.
Net operating cash outflow for the June quarter was around A$2.87 million, including approximately A$1.80 million directed toward research and clinical activities.
The company also reported a full-year loss of around A$7.0 million and net Assets of approximately A$14.2 million.
This means funding remains directly linked to the pace at which Prescient can progress PTX-100 and its broader pipeline.
Additional capital would extend the runway toward the December review and the planned second committee review after 40 evaluable patients are reached.
The limits of a milestone
The latest development is an enrolment milestone rather than a clinical efficacy result.
That distinction is important.
Reaching 20 evaluable patients indicates that the study is progressing through its planned recruitment framework, but it does not show whether PTX-100 is producing durable clinical benefit.
Similarly, orphan drug and fast-track designations are regulatory mechanisms designed to facilitate development in areas of unmet need. They are not endorsements of efficacy.
The Dose Optimisation Committee review should also be viewed in context.
Its role is to assess safety and dosing and provide guidance on continuation of the study. It is not equivalent to a pivotal clinical readout or regulatory decision.
Even if Phase 2a results are encouraging, additional clinical work would still be required before PTX-100 could approach commercialisation.
What to watch
The first area to monitor is the share purchase plan and whether Prescient secures the funding needed to support the next stages of development.
The second is the December Dose Optimisation Committee review.
Investors will be watching what the company discloses following that meeting, particularly around dosing, safety and the recommended path forward.
The third is recruitment toward 40 evaluable patients.
That milestone is expected to support a further review during the first half of 2027.
For Prescient Therapeutics (ASX:PTX), the current development represents progress in trial execution rather than proof of therapeutic success. The next meaningful step will be whether the committee review and subsequent patient data support continued development of PTX-100.




_11_20_2026_20_27_34_097200.jpg)

Please wait processing your request...